Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WNQ205
- Development stage
- Preclinical
- Lead developer
- Staidson Biopharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WNQ205 is a small molecule agonist of Toll-like receptor 8 (TLR8) being developed by Staidson (Beijing) Biopharmaceutical for the treatment of chronic hepatitis B virus (HBV) infection. As an innate immune stimulator, WNQ205 is designed to activate myeloid cells, such as monocytes and myeloid dendritic cells, to produce pro-inflammatory cytokines including IL-12 and TNF-alpha. This activation is intended to promote a Th1-type immune response and enhance the body's ability to clear HBV-infected hepatocytes. WNQ205 is currently in the preclinical stage of development and is part of Staidson's broader pipeline of anti-infective and immunotherapeutic candidates.
02
Targets
TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on WNQ205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WNQ205.